Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PELOPS: Palbociclib and Endocrine Therapy in Early-Stage Breast Cancer
NCT02764541Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2016
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in breast cancer, sponsored by Dana-Farber Cancer Institute. Started May 2016; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02764541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764541.